158 related articles for article (PubMed ID: 34870192)
1. Generic Pharmaceuticals as a Source of Diuretic Contamination in Athletes Subject to Sport Drug Testing.
Eichner A; Lewis LA; Leonard B; Wagoner RMV; Eichner D; Fedoruk MN
Front Sports Act Living; 2021; 3():692244. PubMed ID: 34870192
[TBL] [Abstract][Full Text] [Related]
2. Detection of the diuretic hydrochlorothiazide in a doping control urine sample as the result of a non-steroidal anti-inflammatory drug (NSAID) tablet contamination.
Helmlin HJ; Mürner A; Steiner S; Kamber M; Weber C; Geyer H; Guddat S; Schänzer W; Thevis M
Forensic Sci Int; 2016 Oct; 267():166-172. PubMed ID: 27611956
[TBL] [Abstract][Full Text] [Related]
3. The use of performance-enhancing substances (doping) by athletes in Saudi Arabia.
Al Ghobain M
J Family Community Med; 2017; 24(3):151-155. PubMed ID: 28932159
[TBL] [Abstract][Full Text] [Related]
4. Multiple incidence of the prescription diuretic hydrochlorothiazide in compounded nutritional supplements.
Favretto D; Visentin S; Scrivano S; Roselli E; Mattiazzi F; Pertile R; Vogliardi S; Tucci M; Montisci M
Drug Test Anal; 2019 Mar; 11(3):512-522. PubMed ID: 30194914
[TBL] [Abstract][Full Text] [Related]
5. The abuse of diuretics as performance-enhancing drugs and masking agents in sport doping: pharmacology, toxicology and analysis.
Cadwallader AB; de la Torre X; Tieri A; Botrè F
Br J Pharmacol; 2010 Sep; 161(1):1-16. PubMed ID: 20718736
[TBL] [Abstract][Full Text] [Related]
6. A synopsis of the adverse analytical and atypical findings between 2005 and 2011 from the Doping Control Laboratory of Athens in Greece.
Kioukia-Fougia N; Fragkaki A; Kiousi P; Leontiou IP; Dimopoulou H; Tsivou M; Lyris E; Georgakopoulos C
J Anal Toxicol; 2014; 38(1):16-23. PubMed ID: 24194481
[TBL] [Abstract][Full Text] [Related]
7. Investigating the use of stimulants in out-of-competition sport samples.
Boghosian T; Mazzoni I; Barroso O; Rabin O
J Anal Toxicol; 2011 Nov; 35(9):613-6. PubMed ID: 22080900
[TBL] [Abstract][Full Text] [Related]
8. The Athlete Biological Passport: an integral element of innovative strategies in antidoping.
Vernec AR
Br J Sports Med; 2014 May; 48(10):817-9. PubMed ID: 24659508
[TBL] [Abstract][Full Text] [Related]
9. An (un)desirable trade of harms? How elite athletes might react to medically supervised 'doping' and their considerations of side-effects in this situation.
Overbye M
Int J Drug Policy; 2018 May; 55():14-30. PubMed ID: 29477956
[TBL] [Abstract][Full Text] [Related]
10. Doping control from a global and national perspective.
Fraser AD
Ther Drug Monit; 2004 Apr; 26(2):171-4. PubMed ID: 15228160
[TBL] [Abstract][Full Text] [Related]
11. Narrowing the gap between the number of athletes who dope and the number of athletes who are caught: scientific advances that increase the efficacy of antidoping tests.
Botrè F; de la Torre X; Donati F; Mazzarino M
Br J Sports Med; 2014 May; 48(10):833-6. PubMed ID: 24668049
[TBL] [Abstract][Full Text] [Related]
12. Challenges and perspectives in anti-doping testing.
Schamasch P; Rabin O
Bioanalysis; 2012 Jul; 4(13):1691-701. PubMed ID: 22831484
[TBL] [Abstract][Full Text] [Related]
13. Detection of GH abuse in sport: Past, present and future.
Barroso O; Schamasch P; Rabin O
Growth Horm IGF Res; 2009 Aug; 19(4):369-74. PubMed ID: 19482501
[TBL] [Abstract][Full Text] [Related]
14. The forensic response after an adverse analytical finding (doping) involving a selective androgen receptor modulator (SARM) in human athlete.
Kintz P
J Pharm Biomed Anal; 2022 Jan; 207():114433. PubMed ID: 34715583
[TBL] [Abstract][Full Text] [Related]
15. Dietary Supplements as a Major Cause of Anti-doping Rule Violations.
Lauritzen F
Front Sports Act Living; 2022; 4():868228. PubMed ID: 35399596
[TBL] [Abstract][Full Text] [Related]
16. Measurement uncertainty in anti-doping quantitative analysis for prohibited threshold substances.
Barroso O; Miller J; Squirrell A; Westwood S
Bioanalysis; 2012 Jul; 4(13):1653-65. PubMed ID: 22831481
[TBL] [Abstract][Full Text] [Related]
17. Formation of the diuretic chlorazanil from the antimalarial drug proguanil--implications for sports drug testing.
Thevis M; Geyer H; Thomas A; Tretzel L; Bailloux I; Buisson C; Lasne F; Schaefer MS; Kienbaum P; Mueller-Stoever I; Schänzer W
J Pharm Biomed Anal; 2015 Nov; 115():208-13. PubMed ID: 26226108
[TBL] [Abstract][Full Text] [Related]
18. Medication use in athletes selected for doping control at the Sydney Olympics (2000).
Corrigan B; Kazlauskas R
Clin J Sport Med; 2003 Jan; 13(1):33-40. PubMed ID: 12544162
[TBL] [Abstract][Full Text] [Related]
19. Neurostimulation, doping, and the spirit of sport.
Pugh J; Pugh C
Neuroethics; 2021; 14(Suppl 2):141-158. PubMed ID: 34824648
[TBL] [Abstract][Full Text] [Related]
20. The use of prohibited substances for therapeutic reasons in athletes affected by endocrine diseases and disorders: the therapeutic use exemption (TUE) in clinical endocrinology.
Di Luigi L; Pigozzi F; Sgrò P; Frati L; Di Gianfrancesco A; Cappa M
J Endocrinol Invest; 2020 May; 43(5):563-573. PubMed ID: 31734891
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
